The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

NCT ID: NCT04633733

Last Updated: 2020-11-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-22
• Study Completion Date: 2021-01-31

Brief Summary

This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in healthy male subjects.

Detailed Description

To evaluate the pharmacokinetic interaction by comparing of pharmacokinetic parameters when administered HL237(or tacrolimus) between with tacrolimus(or HL237) and without tacrolimus(or HL237).

Conditions

Healthy Male Volunteers

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Single arm

This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).

Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days

Group Type: EXPERIMENTAL

HL237 tablet

Intervention Type: DRUG

HL237 400mg will be administered orally twice a day.

tacrolimus capsule

Intervention Type: DRUG

tacrolimus 5mg will be administered orally once a day.

Interventions

HL237 tablet

HL237 400mg will be administered orally twice a day.

Intervention Type: DRUG

tacrolimus capsule

tacrolimus 5mg will be administered orally once a day.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male, 19 years ≤ age ≤ 45
• Body weight ≥ 50kg and 18.5 ≤ BMI ≤ 29.9kg/m2
• Subjects are agree to use contraceptives that protocol suggest and not provide sperm for up to 2 months after the last administration of the investigational drug
• Volunteer

Exclusion Criteria

• Subject with serious cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
• Subject with symptoms of acute disease within 28 days prior to investigational products dosing
• Subject with medical history which able to affect absorption, distribution, metabolism and excretion of drug
• Subject with hypersensitive reaction to following drug or history of clinically significant hypersensitive reaction to following drug

• Calcineurin inhibitor or Macrolides
• HL237
• Subject with clinically significant active chronic disease
• Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucosegalactose malabsorption
• Subjects who showed one or more of the following in a screening test including a retest

• AST, ALT > UNL (upper normal limit) x 2.5
• Creatinine clearance =< 80mL/min (Cockcroft-Gault GFR = (140-age) * (Wt in kg) / (72 * Cr))
• Results of ECG, QTc > 450 msec
• Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus antibody, anti-Human Immunodeficiency virus antibody or venereal disease research laboratory test
• Use of any prescription medication within 14 days prior to study medication dosing
• Use of any over-the-counter(OTC) medication within 7 days prior to study medication dosing
• Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)
• Subject who is not able to taking standard meals provided by the institution
• Subject with whole blood donation within 60 days, component blood donation within 20 days
• Subjects receiving blood transfusion within 30 days prior to study medication dosing
• Participation in any clinical investigation within 6 months prior to study medication dosing
• Use of any medication effected on drug enzyme induction or inhibition such as barbitals within 30 days prior to study medication dosing
• Subjects who have continuously consumed grapefruit juice or caffeine (grapefruit juice or caffeine > 5 cups/day), or who can't refrain from intake during hospitalization
• Subjects who have continued to drink alcohol (alcohol> 30 g/day) or who can't quit drinking during hospitalization
• Severe heavy smoker(cigarette > 10 cigarettes per day) or subjects who can't quit smoking during hospitalization
• Subjects that the investigator deems unsuitable for participation in the clinical trial due to laboratory test results or other excuse such as non-responding to request or instruction by investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Hanlim Pharm. Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Korea Univertisy Anam Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

HL237-103

Identifier Type: -

Identifier Source: org_study_id